Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12615000998549
ACTRN12615000998549
Recruiting
未知

Detection of Epidermal Growth Factor Receptor (EGFR) gene mutations in Lung cancer patients in New Zealand

Auckland UniServices Ltd0 sites2,000 target enrollmentSeptember 24, 2015
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsung cancerLung cancerCancer - Lung - Non small cell

Overview

Phase
未知
Intervention
Not specified
Conditions
ung cancer
Sponsor
Auckland UniServices Ltd
Enrollment
2000
Status
Recruiting
Last Updated
6 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
September 24, 2015
End Date
TBD
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patients residing in New Zealand presenting with non\-small cell lung cancer of the non\-squamous or not\-otherwise\-specified morphological subtypes over a two year period.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 1
A Phase 1 Study of Epidermal Growth Factor Receptor (EGFR) Targeted, PaclitaxelLoaded EnGeneIC Delivery Vehicles (Erbitux®EDVsPac) in Patients with Advanced SolidTumoursAdvanced Solid TumoursCancer - Other cancer types
ACTRN12609000672257EnGeneIC Pty Ltd32
Suspended
Phase 2
Panitumumab as second line therapy for advanced pancreatic ductal adenocarcinoma with wild-type KRAS geneKRAS wild-type unresectable or metastatic pancreatic ductal adenocarcinomaCancer - Pancreatic
ACTRN12617000540314Dr Daniel Croagh24
Withdrawn
Phase 2
The Effects of Epidermal Growth Factor Receptor (EGFR) Inhibition on Pulmonary Arterial Hypertension Associated with Systemic Sclerosis A phase II controlled open-label safety and efficacy study.high pulmonary vascular pressure associated with scleroderma100192801001076110037454
NL-OMON30491Vrije Universiteit Medisch Centrum20
Completed
Not Applicable
The effects of epidermal growth factor receptor inhibition on pulmonary arterial hypertension associated with systemic sclerosisSclerosis-associated Pulmonary Arterial Hypertension (SScPAH)Circulatory SystemPulmonary Arterial Hypertension
ISRCTN75611179VU University Medical Centre (The Netherlands)20
Completed
Not Applicable
Frequency of EGFR Mutations in Latinos/Hispanics With Non-Small Cell Lung CancerNon-Small-Cell Lung Carcinoma
NCT01255150National Cancer Institute (NCI)15